Latest news with #PharmaEmail
Yahoo
31-03-2025
- Business
- Yahoo
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
Company announcement – No. 8 / 2025 Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S ("the Company" or 'Zealand Pharma') (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 5 / 2025 dated March 20, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of March 31, 2025. Date Number of shares(nominal value of DKK 1 each) Share capital(nominal value in DKK) Number of voting rights March 31, 2025 71,051,296 71,051,296 71,051,296 The Company's Articles of Association are available on the Company's website # # # About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactAdam LangeInvestor Relations OfficerZealand PharmaEmail: alange@ Anna Krassowska, PhDVice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: akrassowska@ Neshat AhmadiInvestor Relations ManagerZealand PharmaEmail: neahmadi@ in to access your portfolio
Yahoo
25-03-2025
- Business
- Yahoo
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 24 March 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 24 March 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,106,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.00% of the total share capital and 10.05% of the total voting rights in Zealand Pharma A/S. Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. (Dutch registration no. 75092395), which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk. Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,106,191 shares (each share carrying one vote), corresponding to 10.00% of the total share capital and 10.05% of the total voting rights in Zealand Pharma A/S. Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk. Please see further details in the attached notification form. # # # About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a team in the U.S. For more information about Zealand Pharma's business and activities, please visit ContactAnna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: akrassowska@ Adam Lange (Investors)Investor Relations OfficerZealand PharmaEmail: alange@ Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@ Attachments 20250324 FSA - Standardformular english Van Herk Investments BV_signed 20250324 FSA - Standardformular english Van Herk Management Services BV_signed
